Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars | Emerging Biosimilars | Oncology | Herzuma | Germany | Wave 1 | 2018

Login to access report north_east
Contact sales account_box

Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical oncologists’ awareness of the agent in order to gauge its impact in the commercially lucrative breast cancer market and the gastroesophageal cancer market. The series investigates perceptions of Herzuma, drivers of and barriers to its use, and future-use expectations. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.

QUESTIONS ANSWERED

  • Are German medical oncologists aware of Herzuma?
  • What are the drivers of prescribing Herzuma? What is the current level of Herzuma use, and how is that changing over time?
  • Are German physicians prescribing Herzuma in combination with Perjeta?
  • Have physicians experienced pressures to prescribe Herzuma to patients?
  • What promotional messages are sales representatives employing for Herzuma and Herceptin?

PRODUCT DESCRIPTION

Emerging Biosimilars (Germany) is a three-wave series based on primary research data collected at 1 month, 6 months, and 12 months post-commercial launch with German physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

RELEASE DATE

Wave 1: September 2018

Wave 2: TBC 2019

Wave 3: TBC 2019

GEOGRAPHY

Germany

PRIMARY RESEARCH

Survey of 60 medical oncologists

Key metrics included

  • Unaided and Aided Awareness of Herzuma
  • Familiarity with and Impressions of Herzuma
  • Prescriber and Nonprescriber Profiles
  • Willingness to Prescribe Herzuma
  • Performance of Herzuma on Key Attributes
  • Sales Representative Frequency, Reach, and Satisfaction
  • Benchmarking Against Previously Launched Biosimilars
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
north_east
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
north_east
Report
Biosimilars – Access & Reimbursement – Access & Reimbursement Global Landscape
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
north_east
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 719 currently available and novel biosimilar products, detailing…
north_east
Report
Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2023, sales of branded biologics for oncology, immunology, endocrinology, respiratory, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $156 billion in the major…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east